Low‐Dose Cytarabine Plus G‐ CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study
Open Access
- 30 September 2026
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 15 (10)
Abstract
This retrospective secondary analysis of the multicenter randomized CALS III‐AML18 trial evaluated the efficacy and safety of low‐dose chemotherapy (LDC) compared with standard‐dose chemotherapy (SDC) in children with M2 acute myeloid leukemia (AML‐M2). A total of 221 children were included, with 109 in the LDC arm and 112 in the SDC arm. The complete remission (CR)/CR with incomplete recovery (CRi) rates after induction I and II were 67.0% versus 70.5% ( p = 0.568) and 84.4% versus 89.3% ( p = 0.740), respectively. The 3 year overall survival (OS) rates were 81.2% ± 3.9% and 86.9% ± 3.3% in the LDC and SDC arms, respectively ( p = 0.304). The corresponding 3 year relapse‐free survival (RFS) rates were 82.0% ± 3.8% and 88.1% ± 3.1% ( p = 0.205), and the 3 year event‐free survival (EFS) rates were 62.1% ± 4.8% and 70.8% ± 4.4% ( p = 0.218). Among patients with KIT mutations, outcomes were poorer in the LDC arm than in the SDC arm, including 3 year OS (67.1% ± 8.7% vs. 91.5% ± 4.1%, p = 0.011), RFS (70.6% ± 7.8% vs. 87.5% ± 4.8%, p = 0.038), and EFS (49.2% ± 8.7% vs. 81.0% ± 5.7%, p = 0.002). Among patients who developed sepsis, grade 3–5 events were less frequent in the LDC arm than in the SDC arm (33.3% vs. 78.8%, p < 0.001). LDC was also associated with faster neutrophil and platelet recovery, lower transfusion requirements, and reduced treatment costs during induction. No statistically significant differences in remission or survival outcomes were observed between LDC and SDC, while the LDC regimen showed a lower treatment‐related burden. These findings support further evaluation of LDC as a toxicity‐sparing induction strategy in selected pediatric patients with AML‐M2. The poorer outcomes observed among patients with KIT mutations warrant caution when considering treatment de‐intensification in this subgroup.Keywords
Funding Information
- National Natural Science Foundation of China (82141125)
- Science and Technology Commission of Shanghai Municipality (21Y31900302)
- Science and Technology Commission of Shanghai Municipality (24Y12800602)
- Shanghai Municipal Hospital Development Center (SHDC12019121)
- National Key Research and Development Program of China (2022YFC2705003)
- National Key Research and Development Program of China (2023YFC2706301)
This publication has 17 references indexed in Scilit:
- Overexpression of TREM1 predicts poor prognosis and chemotherapy resistance in Egyptian acute myeloid leukemia associated with FLT3 internal tandem duplication and CD123 expression and stemness signaturesDiscover Oncology, 2026
- Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort studyBlood Cancer Journal, 2023
- Children's Oncology Group's 2023 blueprint for research: Myeloid neoplasmsPediatric Blood & Cancer, 2023
- Distinct genomic landscape of Chinese pediatric acute myeloid leukemia impacts clinical risk classificationNature Communications, 2022
- How I treat pediatric acute myeloid leukemiaBlood, 2021
- Ecological principle meets cancer treatment: treating children with acute myeloid leukemia with low-dose chemotherapyNational Science Review, 2019
- Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004Blood Cancer Journal, 2016
- Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemiaBlood, 2006
- Effect of Priming with Granulocyte Colony-Stimulating Factor on the Outcome of Chemotherapy for Acute Myeloid LeukemiaNew England Journal of Medicine, 2003
- Acute myeloblastic leukemia (ANLL-M2) with t(8;21)(q22;q22) variant expressing lymphoid but not myeloid surface antigens with a high number of G-CSF receptorsLeukemia Research, 1993